P. Yeung

发表

CAT-8015: A Second-Generation Pseudomonas Exotoxin A–Based Immunotherapy Targeting CD22-Expressing Hematologic Malignancies

I. Pastan, R. Kreitman, R. Herbst, 2009, Clinical Cancer Research.

Abstract 1907: Wnt pathway antagonist OMP-54F28 (FZD8-Fc) inhibits tumor growth and reduces tumor-initiating cell frequency in patient-derived hepatocellular carcinoma and ovarian cancer xenograft models

M. Fischer, J. Lewicki, A. Gurney, 2014 .

Abstract A30: Predictive and pharmacodynamic biomarkers of vantictumab (OMP-18R5; anti-Frizzled) in non-small cell lung cancer

M. Fischer, J. Lewicki, T. Hoey, 2015 .

Abstract A030: Biomarker study of vantictumab plus paclitaxel in HER2- breast cancer patients

J. Lewicki, F. Cattaruzza, G. Argast, 2018 .

Abstract 4367: Discovery and evaluation of pharmacodynamic and predictive biomarkers for anti-RSPO3, a treatment that reduces tumor growth and cancer stem cell frequency in patient derived xenograft tumor models

M. Fischer, J. Lewicki, A. Gurney, 2015 .

Abstract 4652: Effects of anti-DLL4 treatment on non-small cell lung cancer (NSCLC) human xenograft tumors

M. Fischer, J. Lewicki, A. Gurney, 2016 .

Nm23 gene expression in gastric carcinoma: an immunohistochemical study.

P. Marr, M. Sarris, P. Yeung, 1998, The Australian and New Zealand journal of surgery.

Abstract 2834: Anti-DLL4 treatment inhibits melanoma tumor growth, recurrence, metastases, and reduces frequency of cancer stem cells in a clinically relevant tumor model in NOD/SCID mice

M. Fischer, J. Lewicki, A. Gurney, 2011 .

Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer Types.

M. Fischer, J. Lewicki, A. Gurney, 2016, Cancer research.

Result in an In Vivo Response Directed at the Does Not β Cell Epitope in Human IFN- T + Elimination of an Immunodominant CD4

Marcia Stickler, Fiona A. Harding, Peter Yeung, 2013 .

Abstract 3129: Predictive biomarker identification for response to vantictumab (OMP-18R5; anti-Frizzled) using primary patient-derived human pancreatic tumor xenografts

M. Fischer, J. Lewicki, A. Gurney, 2016 .

Abstract 404: Development of a RSPO3 CLIA-validated assay as a predictive biomarker for response to anti-RSPO3 antibody treatment in patients with solid tumors

M. Fischer, J. Lewicki, A. Gurney, 2016 .

Therapeutic targeting of tumor-derived R-spondin attenuates β-catenin signaling and tumorigenesis in multiple cancer types

J. Lewicki, A. Gurney, T. Hoey, 2015 .